Vaccine and Therapeutic Options To Control Chikungunya Virus

Powers, Ann M.

doi:10.1128/cmr.00104-16

Cited by 121 publications

(108 citation statements)

References 140 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Codagenix and SynVaccine have been established to investigate novel vaccine strategies using synthetic virology technology. But most of the focuses are on human viral pathogens, which include influenza virus (Mueller et al., ), poliovirus (Sanders, Edo‐Matas, Papic, Schuitemaker, & Custers, ), Chikungunya virus (Powers, ) and HIV (Martrus, Nevot, Andres, Clotet, & Martinez, ). Among the approaches to construct attenuated live synthetic viruses include genome‐scale changes in codon‐pair bias (Mueller et al., ) and codon de‐optimization (Evenson et al., ; Martínez, Jordan‐Paiz, Franco, & Nevot, ).…”

Section: Future Perspectivementioning

confidence: 99%

Molecular biology of Macrobrachium rosenbergii nodavirus infection in giant freshwater prawn

Low

Yusoff²,

Kuppusamy³

et al. 2018

Journal of Fish Diseases

View full text Add to dashboard Cite

Macrobrachium rosenbergii nodavirus (MrNV) has been threatening the giant freshwater prawn aquaculture since 1997, causing white tail disease in the prawn species that leads to 100% lethality of the infected postlarvae. Comprehension of the viral infectivity and pathogenesis at molecular biology level has recently resolved the viral capsid protein and evidenced the significant difference in the viral structural protein compared to other nodaviruses that infect fish and insect. Cumulative researches have remarked the proposal to assert MrNV as a member of new genus, gammanodavirus to the Nodaviridae family. The significance of molecular biology in MrNV infection is being highlighted in this current review, revolving the viral life cycle from virus binding and entry into host, virus replication in host cell, to virus assembly and release. The current review also highlights the emerging aptamers technology that is also known as synthetic antibody, its application in disease diagnosis, and its prophylactic and therapeutic properties. The future perspective of synthetic virology technology in understanding viral pathogenesis, as well as its potential in viral vaccine development, is also discussed.

show abstract

Section: Future Perspectivementioning

confidence: 99%

Molecular biology of Macrobrachium rosenbergii nodavirus infection in giant freshwater prawn

Low

Yusoff²,

Kuppusamy³

et al. 2018

Journal of Fish Diseases

View full text Add to dashboard Cite

show abstract

“…These factors combine to determine the distribution and intensity of arboviral transmission, and generate often complex and highly heterogeneous patterns of exposure and infection [20,21]. As safe and effective vaccines for DENV, CHIKV and ZIKV viruses are not yet available [22][23][24][25][26][27], control of the Aedes mosquito vectors remains a primary strategy for reducing transmission [28][29][30].Knowledge of where and when humans are at greatest risk of exposure to infected mosquito bites is vital for prediction of transmission intensity and effective deployment of vector control [31][32][33][34]. In the case of malaria, this information is used to estimate a time or site-specific "Entomological Inoculation Rate" (EIR); defined as the number of infected mosquito bites a person is expected to receive.…”

mentioning

confidence: 99%

The Mosquito Electrocuting Trap As An Exposure-Free Method For Measuring Human Biting Rates ByAedesMosquito Vectors

Ortega-López

Pondeville

Kohl

et al. 2019

Preprint

View full text Add to dashboard Cite

BackgroundEntomological monitoring of Aedes vectors has largely relied on surveillance of larvae, pupae and non-host-seeking adults, which have been poorly correlated with human disease incidence. Exposure to mosquito-borne diseases can be more directly estimated using Human Landing Catches (HLC), although this method is not recommended for Aedes-borne arboviruses.We evaluated a new method previously tested with malaria vectors, the Mosquito Electrocuting Trap (MET) as an exposure-free alternative for measuring landing rates of Aedes mosquitoes on people. Aims were to 1) compare the MET to the BG-sentinel (BGS) trap gold standard approach for sampling host-seeking Aedes vectors; 2) characterize the diel activity of Aedes vectors and their association with microclimatic conditions. MethodsThe study was conducted over 12 days in Quinindé -Ecuador in May 2017. Mosquito sampling stations were set up in the peridomestic area of four houses. On each day of sampling, each house was allocated either a MET or a BGS trap, which were rotated amongst the four houses daily in a Latin square design. Mosquito abundance and microclimatic conditions were recorded hourly at each sampling station between 07:00-19:00 hours to assess variation between vector abundance, trapping methods, and environmental conditions. All Aedes aegypti females were tested for the presence of Zika (ZIKV), dengue (DENV) and chikungunya (CHIKV) viruses.3 ResultsA higher number of Ae. aegypti females were found in MET than in BGS collections, although no statistically significant differences in mean Ae. aegypti abundance between trapping methods were found. Both trapping methods indicated female Ae. aegypti had bimodal patterns of host seeking, being highest during early morning and late afternoon hours. Mean Ae. aegypti daily abundance was negatively associated with daily temperature. No infection by ZIKV, DENV or CHIKV was detected in any Aedes mosquitoes caught by either trapping method. ConclusionWe conclude the MET performs at least as well as the BGS standard, and offers the additional advantage of direct measurement of per capita human biting rates. If detection of arboviruses can be confirmed in MET-collected Aedes in future studies, this surveillance method could provide a valuable tool for surveillance and prediction on human arboviral exposure risk. BACKGROUNDMosquito--borne viruses (arboviruses) are an important cause of diseases in humans and animals. In 2017, estimates suggested that mosquitoes were responsible for approximately 137 millions human arboviral infections with dengue (DENV), chikungunya (CHIKV), and Zika virus (ZIKV) being the most important [1]. Arbovirus transmission to humans depends on multiple factors that involve spatial movement and immunity of human populations [2-7], socioeconomic factors and access to basic services (especially water) [8][9][10][11], and the ecology and distribution of the mosquito vectors that transmit them [12][13][14][15][16][17][18][19]. These factors combine to determine the distribution and intens...

show abstract

“…In the United Kingdom, and subsequent to the Ebola outbreak in West Africa, vaccine networks for human and veterinary vaccines have formed to prioritize vaccine efforts in these respective contexts [61], while the Department of Health, together with Innovate UK, has supported R&D of vaccine candidates for the prioritized pathogens [62]. As a result of these global initiatives, a number of candidate vaccines are being developed for emerging bacterial and viral pathogens, examples of which, although by no means exhaustive, are cited here [63][64][65][66][67][68][69][70][71][72][73][74]. WHO reports ongoing global vaccine R&D efforts [75] and also tracks the progress of clinical trials for emerging pathogens [76].…”

Section: Vaccine Requirementsmentioning

confidence: 99%

Vaccines for emerging pathogens: prospects for licensure

Williamson

Westlake

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Globally, there are a number of emerging pathogens. For most, there are no licensed vaccines available for human use, although there is ongoing research and development. However, given the extensive and increasing list of emerging pathogens and the investment required to bring vaccines into clinical use, the task is huge. Overlaid on this task is the risk of anti‐microbial resistance (AMR) acquisition by micro‐organisms which can endow a relatively harmless organism with pathogenic potential. Furthermore, climate change also introduces a challenge by causing some of the insect vectors and environmental conditions prevalent in tropical regions to begin to spread out from these traditional areas, thus increasing the risk of migration of zoonotic disease. Vaccination provides a defence against these emerging pathogens. However, vaccines for pathogens which cause severe, but occasional, disease outbreaks in endemic pockets have suffered from a lack of commercial incentive for development to a clinical standard, encompassing Phase III clinical trials for efficacy. An alternative is to develop such vaccines to request US Emergency Use Authorization (EUA), or equivalent status in the United States, Canada and the European Union, making use of a considerable number of regulatory mechanisms that are available prior to licensing. This review covers the status of vaccine development for some of the emerging pathogens, the hurdles that need to be overcome to achieve EUA or an equivalent regional or national status and how these considerations may impact vaccine development for the future, such that a more comprehensive stockpile of promising vaccines can be achieved.

show abstract

Vaccine and Therapeutic Options To Control Chikungunya Virus

Cited by 121 publications

References 140 publications

Molecular biology of Macrobrachium rosenbergii nodavirus infection in giant freshwater prawn

Molecular biology of Macrobrachium rosenbergii nodavirus infection in giant freshwater prawn

The Mosquito Electrocuting Trap As An Exposure-Free Method For Measuring Human Biting Rates ByAedesMosquito Vectors

Vaccines for emerging pathogens: prospects for licensure

Contact Info

Product

Resources

About